The Ron receptor promotes prostate tumor growth in the TRAMP mouse model

Oncogene

Volumn 30, Issue 50, 2011, Pages 4990-4998

  Thobe, M N ^a   Gray, J K ^a   Gurusamy, D ^a   Paluch, A M ^a   Wagh, P K ^a   Pathrose, P ^a   Lentsch, A B ^a   Waltz, S E ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

hepatoctye growth factor like protein; MST1R; prostate cancer; receptor tyrosine kinase; Ron receptor

Indexed keywords

ANGIOGENIC FACTOR; CXCL2 CHEMOKINE; I KAPPA B; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENETIC ENGINEERING; HYPOTHESIS; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RON GENE; TRANSGENIC ANIMAL; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; UPREGULATION; WILD TYPE;

ANIMALS; CELL PROLIFERATION; CELL SURVIVAL; CHEMOKINE CXCL2; CROSSES, GENETIC; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MICE; MICE, KNOCKOUT; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PROSTATIC NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 25;

MURINAE; MUS;

EID: 83555173590     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.205     Document Type: Article

References (35)

1. Agus DB, Scher HI, Higgins B, Fox WD, Heller G, Fazzari M et al. (1999). Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and-independent human xenograft models. Cancer Res 59: 4761-4764. (Pubitemid 29472871)
2. Becker CM, Farnebo FA, Iordanescu I, Behonick DJ, Shih MC, Dunning P et al. (2002). Gene therapy of prostate cancer with the soluble vascular endothelial growth factor receptor Flk1. Cancer Biol Ther 1: 548-553.
3. Chan EL, Peace BE, Collins MH, Toney-Earley K, Waltz SE. (2005). Ron tyrosine kinase receptor regulates papilloma growth and malignant conversion in a murine model of skin carcinogenesis. Oncogene 24: 479-488. (Pubitemid 40188595)
4. Chen YQ, Zhou YQ, Angeloni D, Kurtz AL, Qiang XZ, Wang MH. (2000). Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell lines. Exp Cell Res 261: 229-238.
5. Chen YQ, Zhou YQ, Fisher JH, Wang MH. (2002). Targeted expression of the receptor tyrosine kinase RON in distal lung epithelial cells results in multiple tumor formation: oncogenic potential of RON in vivo. Oncogene 21: 6382-6386.
6. De Bono JS, Attard G, Adjei A, Pollak MN, Fong PC, Haluska P et al. (2007). Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 13: 3611-3616. (Pubitemid 46955123)
7. Dhanasekaran SM, Dash A, Yu J, Maine IP, Laxman B, Tomlins SA et al. (2005). Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty. FASEB J 19: 243-245. (Pubitemid 40189269)
8. Gaudino G, Follenzi A, Naldini L, Collesi C, Santoro M, Gallo KA et al. (1994). RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J 13: 3524-3532. (Pubitemid 24246189)
9. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ et al. (1996). Metastatic prostate cancer in a transgenic mouse. Cancer Res 56: 4096-4102. (Pubitemid 26304996)
10. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO et al. (1995). Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92: 3439-3443.
11. Iwama A, Yamaguchi N, Suda T. (1996). STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking site conserved among the HGF receptor family. EMBO J 15: 5866-5875. (Pubitemid 26375508)
12. Kassis J, Moellinger J, Lo H, Greenberg NM, Kim HG, Wells A. (1999). A role for phospholipase C-gamma-mediated signaling in tumor cell invasion. Clin Cancer Res 5: 2251-2260. (Pubitemid 29399285)
13. Kojima S, Inahara M, Suzuki H, Ichikawa T, Furuya Y. (2009). Implications of insulin-like growth factor-I for prostate cancer therapies. Int J Urol 16: 161-167.
14. Lapointe J, Li C, Giacomini CP, Salari K, Huang S, Wang P et al. (2007). Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 67: 8504-8510. (Pubitemid 47437424)
15. Leonis MA, Toney-Earley K, Degen SJ, Waltz SE. (2002). Deletion of the Ron receptor tyrosine kinase domain in mice provides protection from endotoxin-induced acute liver failure. Hepatology 36: 1053-1060. (Pubitemid 35253420)
16. Logan-Collins J, Thomas RM, Yu P, Jaquish D, Mose E, French R et al. (2010). Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers. Cancer Res 70: 1130-1140.
17. Maggiora P, Marchio S, Stella MC, Giai M, Belfiore A, De Bortoli M et al. (1998). Overexpression of the RON gene in human breast carcinoma. Oncogene 16: 2927-2933. (Pubitemid 28383277)
18. Mallakin A, Kutcher LW, McDowell SA, Kong S, Schuster R, Lentsch AB et al. (2006). Gene expression profiles of Mst1r-deficient mice during nickel-induced acute lung injury. Am J Respir Cell Mol Biol 34: 15-27. (Pubitemid 43042853)
19. Meyer SE, Waltz SE, Goss KH. (2009a). The Ron receptor tyrosine kinase is not required for adenoma formation in Apc(Min/+) mice. Mol Carcinogen 48: 995-1004.
20. Meyer SE, Zinser GM, Stuart WD, Pathrose P, Waltz SE. (2009b). The Ron receptor tyrosine kinase negatively regulates mammary gland branching morphogenesis. Dev Biol 333: 173-185.
21. O'Toole JM, Rabenau KE, Burns K, Lu D, Mangalampalli V, Balderes P et al. (2006). Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res 66: 9162-9170. (Pubitemid 44521136)
22. Peace BE, Toney-Earley K, Collins MH, Waltz SE. (2005). Ron receptor signaling augments mammary tumor formation and metastasis in a murine model of breast cancer. Cancer Res 65: 1285-1293. (Pubitemid 40270155)
23. Ronsin C, Muscatelli F, Mattei MG, Breathnach R. (1993). A novel putative receptor protein tyrosine kinase of the met family. Oncogene 8: 1195-1202. (Pubitemid 23129841)
24. Shen H, Lentsch AB. (2004). Progressive dysregulation of transcription factors NF-kappa B and STAT1 in prostate cancer cells causes proangiogenic production of CXC chemokines. Am J Physiol Cell Physiol 286: C840-C847. (Pubitemid 38543813)
25. Shen H, Schuster R, Lu B, Waltz SE, Lentsch AB. (2006). Critical and opposing roles of the chemokine receptors CXCR2 and CXCR3 in prostate tumor growth. Prostate 66: 1721-1728. (Pubitemid 44893898)
26. Shukla S, Maclennan GT, Marengo SR, Resnick MI, Gupta S. (2005). Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model. Prostate 64: 224-239. (Pubitemid 40980864)
27. Thobe MN, Gurusamy D, Pathrose P, Waltz SE. (2010). The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells. Oncogene 29: 214-226.
28. Thomas RM, Toney K, Fenoglio-Preiser C, Revelo-Penafiel MP, Hingorani SR, Tuveson DA et al. (2007). The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res 67: 6075-6082. (Pubitemid 47037486)
29. Vicentini C, Festuccia C, Gravina GL, Angelucci A, Marronaro A, Bologna M. (2003). Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures. J Cancer Res Clin Oncol 129: 165-174. (Pubitemid 36583697)
30. Wagh PK, Gray JK, Zinser GM, Vasiliauskas J, James L, Monga SP et al. (2011). beta-Catenin is required for Ron receptor-induced mammary tumorigenesis. Oncogene 30: 3694-3704.
31. Wagh PK, Peace BE, Waltz SE. (2008). Met-related receptor tyro-sine kinase Ron in tumor growth and metastasis. Adv Cancer Res 100: 1-33. (Pubitemid 351942429)
32. Waltz SE, Eaton L, Toney-Earley K, Hess KA, Peace BE, Ihlendorf JR et al. (2001). Ron-mediated cytoplasmic signaling is dispensable for viability but is required to limit inflammatory responses. J Clin Invest 108: 567-576. (Pubitemid 32777736)
33. Wang J, Eltoum IE, Lamartiniere CA. (2007). Genistein chemopre-vention of prostate cancer in TRAMP mice. J Carcinogen 6: 3.
34. Wilson CB, Ray M, Lutz M, Sharda D, Xu J, Hankey PA. (2008). The RON receptor tyrosine kinase regulates IFN-gamma production and responses in innate immunity. J Immunol 181: 2303-2310.
35. Zinser GM, Leonis MA, Toney K, Pathrose P, Thobe M, Kader SA et al. (2006). Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation. Cancer Res 66: 11967-11974. (Pubitemid 46094210)